0001209191-21-004572.txt : 20210120 0001209191-21-004572.hdr.sgml : 20210120 20210120202143 ACCESSION NUMBER: 0001209191-21-004572 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210119 FILED AS OF DATE: 20210120 DATE AS OF CHANGE: 20210120 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PRASAD SUYASH CENTRAL INDEX KEY: 0001679129 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39536 FILM NUMBER: 21540122 MAIL ADDRESS: STREET 1: C/O AUDENTES THERAPEUTICS, INC. STREET 2: 101 MONTGOMERY ST., SUITE 2650 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc. CENTRAL INDEX KEY: 0001806310 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 843199512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2280 INWOOD ROAD CITY: DALLAS STATE: TX ZIP: 75235 BUSINESS PHONE: (214) 612-0000 MAIL ADDRESS: STREET 1: 2280 INWOOD ROAD CITY: DALLAS STATE: TX ZIP: 75235 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-01-19 0 0001806310 Taysha Gene Therapies, Inc. TSHA 0001679129 PRASAD SUYASH C/O TAYSHA GENE THERAPIES, INC. 2280 INWOOD ROAD DALLAS TX 75235 0 1 0 0 CMO and Head of R&D Stock Option (Right to Buy) 31.00 2021-01-19 4 A 0 80000 0.00 A 2031-01-19 Common Stock 80000 80000 D 25% of the total number of shares underlying the option shall vest and become exercisable on January 19, 2022 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. /s/ Kamran Alam, Attorney-in-Fact 2021-01-20